Teva Pharmaceutical Files Form 8-A/A for Direct NYSE Listing of Ordinary Shares

Overview of Filing

Teva Pharmaceutical Industries Limited filed Amendment No. 2 to its Registration Statement on Form 8-A (Form 8-A12B/A) with the SEC on September 14, 2026.

Key Highlights

1. Transition from ADSs to Ordinary Shares:

   • Teva terminated its Second Amended and Restated Deposit Agreement with Citibank, N.A. on September 14, 2026.
   • Outstanding American Depositary Shares (ADSs) were converted directly into Ordinary Shares (par value NIS 0.10 per share).
   • The Ordinary Shares are now directly registered and listed on the New York Stock Exchange (NYSE).

2. Share Capital Details:

   • Registered share capital consists of 2,494,343,316 Ordinary Shares.
   • As of August 31, 2026, 1,166,292,643 Ordinary Shares were issued and outstanding, along with 60 deferred shares (NIS 0.10 par value).

3. Transfer Agent:

   • Equiniti Trust Company, LLC acts as the transfer agent and registrar for the Ordinary Shares.